Lucid Diagnostics files for IPO on Nasdaq exchange

By LabPulse.com staff writers

September 23, 2021 -- Lucid Diagnostics has filed for an initial public offering (IPO), and the company's shares will be traded on the Nasdaq stock exchange under the symbol "LUCD."

The number of shares to be offered and the price range for the offering have not yet been determined. Lucid is a majority-owned subsidiary of interventional medical device developer PAVmed.

The IPO will be made only by means of a prospectus, the company said.

Ginkgo Bioworks will go public in SPAC deal worth over $1.6B
Cell programming company Ginkgo Bioworks will go public after it finalizes a $1.6 billion deal with Soaring Eagle Acquisition, a special purpose acquisition...
Illumina completes Grail deal, despite lack of European approval
Illumina has completed its acquisition of cancer diagnostics developer Grail, almost a year after announcing the deal. Illumina said it would run Grail...
Lunit receives $26M funding from Guardant Health
South Korean artificial intelligence (AI) software developer Lunit recently announced a strategic investment of $26 million from Guardant Health....
Ortho files for IPO to sell 70M shares
Ortho Clinical Diagnostics has filed for an initial public offering (IPO) that aims to sell 70 million shares at a price between $20 and $23 per...
Holy Grail: Ilumina nabs cancer testing firm in $8B deal
Illumina has agreed to acquire cancer diagnostics startup Grail for $8 billion in cash and stock. Grail utilizes Illumina's next-generation sequencing...

Copyright © 2021 LabPulse.com

Last Updated bc 9/24/2021 6:35:51 AM